Detecting Cancer Patents (Class 435/6.14)
  • Patent number: 11144545
    Abstract: An automatic service monitor in an information-technology environment performs regular search queries against generated machine data to derive performance measurements. The information technology environment is defined in terms of services provided by entities, and the performance measurements are defined as key performance indicators (KPIs) of the services. Generated machine data used by the search queries pertain to the entities performing the service. Definitional information for the services, entities, and KPIs is administered by a user to control the operation of the service monitor. Various aspects of such definitional information as well as related performance measurement information may be presented in a unified console display tailored to, and organized around, a particular entity. The console display may serve as a central launch point by supporting user interaction to navigate to other specialized monitoring interfaces.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: October 12, 2021
    Assignee: Splunk Inc.
    Inventors: Nicholas Matthew Tankersley, Fang I. Hsiao, Arun Ramani
  • Patent number: 11142801
    Abstract: It is intended to provide a method for determining a tumor. The method for determining a tumor comprises: (1) treating genomic DNA prepared from a subject tissue or cell with bisulfite (the subject tissue or cell is derived from a patient who is affected by a tumor and is determined as (i) having MSI-H of the tumor in MSI examination and/or no or reduced expression of MLH1 in the tumor in immunohistochemical examination, and (ii) having no mutation in MLH1 in genetic examination); 2) amplifying, by PCR, DNA comprising a portion or the whole of MLH1 promoter region from the bisulfite-treated DNA; 3) subjecting the PCR amplification product to ion exchange chromatography to obtain a detection signal; 4) determining whether or not the peak of the detection signal is a peak indicating highly methylated DNA; and 5) determining the tumor as a tumor derived from a patient without Lynch syndrome when the peak is determined as a peak indicating highly methylated DNA.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: October 12, 2021
    Assignees: JAPANESE FOUNDATION FOR CANCER RESEARCH, SEKISUI MEDICAL CO., LTD.
    Inventors: Masami Arai, Sachio Nomura, Yuriko Nemoto, Takuya Yotani
  • Patent number: 11136625
    Abstract: Gene expression signature predictive of cancer patient response to multi-kinase inhibitor is disclosed. Also disclosed are methods predicting the efficacy of the multi-kinase inhibitor for treating cancer in a patient. Also disclosed are methods for distinguishing responders from non-responders to a multi-kinase inhibitor in treating cancer. Also disclosed are methods for treating a cancer patient with a multi-kinase inhibitor.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: October 5, 2021
    Assignee: CROWN BIOSCIENCE, INC. (TAICANG)
    Inventors: Sheng Guo, Daiwei Chen, Juan Zhang, Jie Cai, Henry Qixiang Li
  • Patent number: 11137401
    Abstract: The present invention relates to a method for detecting cancer, comprising measuring the expression of a polypeptide having a reactivity of binding to an antibody against a CAPRIN-1 protein having an amino acid sequence shown in any one of the even-numbered SEQ ID NOS: 2-30 in the Sequence Listing via an antigen-antibody reaction in a sample separated from a living organism, and, a reagent for detecting a cancer comprising the CAPRIN-1 protein or a fragment thereof, an antibody against the CAPRIN-1 protein or a fragment thereof, or a polynucleotide encoding the CAPRIN-1 protein or a fragment thereof.
    Type: Grant
    Filed: August 5, 2009
    Date of Patent: October 5, 2021
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Fumiyoshi Okano, Kana Suzuki
  • Patent number: 11138193
    Abstract: The cost of data-mining is estimated where data-mining services are delivered via a distributed computing system environment. System requirements are estimated for a particular data-mining task for an input data set having specified properties. Estimating system requirements includes applying a partial learning tool to operate on sample data from the input data set.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: October 5, 2021
    Assignee: International Business Machines Corporation
    Inventors: Jakub Marecek, Dimitrios Mavroeidis, Pascal Pompey, Michael Wurst
  • Patent number: 11130988
    Abstract: According to one embodiment, a detection method is a method for detecting a plurality of target nucleic acids in a sample. The method includes (a) preparing a chain-elongation nucleic acid set group, a primer set, and a probe immobilized substrate, (b) obtaining the target nucleic acid and a long-chain nucleic acid group containing a first sub-chain-elongation nucleic acid and a second sub-chain-elongation nucleic acid, (c) obtaining an amplification product group by maintaining the long-chain nucleic acid group and the primer set under amplification conditions, (d) detecting presence/absence and/or an amount of hybridization, and (e) detecting the plurality of target nucleic acids.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: September 28, 2021
    Assignee: KABUSHIKI KAISHA TOSHIBA
    Inventors: Keiko Ito, Koji Hashimoto
  • Patent number: 11130789
    Abstract: Early detection of tumors is a major determinant of survival of patients suffering from tumors, including bladder tumors. Members of the BTM or UBTM family can be highly and consistently accumulated in bladder tumor tissue and other tumor tissue, and/or can be accumulated in urine of patients, and thus are markers for bladder and other types of cancer. In certain embodiments, BTMs or UBTMs can accumulate in the urine, and detection of UBTM family members can be an effective diagnostic approach. In some embodiments, quantitative PCR methods have advantages over microarray methods. In other embodiments, detection and quantification of a plurality of BTMs or UBTMs can increase the sensitivity and specificity of detection of bladder cancer, and therefore provides methods for determining the stage and type of bladder cancer. Kits provide easy, convenient ways for carrying out the methods of this invention.
    Type: Grant
    Filed: July 22, 2005
    Date of Patent: September 28, 2021
    Assignee: Pacific Edge Limited
    Inventors: Parry John Guilford, Natalie Jane Kerr, Robert Craig Pollock
  • Patent number: 11124847
    Abstract: A method for generating a reporter cell line comprises culturing a cell line capable of undergoing two or more consecutive stages of differentiation and performing the targeted insertion of two or more secretable reporter genes into the genome of the cultured cell line to form edited cells. One or more first stage inserted secretable reporter genes are placed under control of promoters for genes canonically expressed during the first stage of differentiation, and one or more second stage inserted secretable reporter genes are placed under control of promoters for genes canonically expressed during the second stage of differentiation but not during the first stage of differentiation. Differentiation of the clonally expanded edited cells is then induced to the first stage of differentiation, thus inducing expression of the first stage inserted secretable reporter genes.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: September 21, 2021
    Assignee: NZUMBE, INC.
    Inventors: James M. Stafford, Michael R. Rountree
  • Patent number: 11118213
    Abstract: A method of analyzing a tumor sample comprising: (a) acquiring a library comprising a plurality of tumor members from a tumor sample; (b) contacting the library with a bait set to provide selected members; (c) acquiring a read for a subgenomic interval from a tumor member from said library; (d) aligning said read; and (e) assigning a nucleotide value (e.g., calling a mutation) from said read for the preselected nucleotide position, thereby analyzing said tumor sample.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: September 14, 2021
    Assignee: Foundation Medicine, Inc.
    Inventors: Doron Lipson, Geoffrey Alan Otto, Alexander N. Parker, Philip James Stephens, Sean R. Downing, Mirna Jarosz, Mikhail G. Shapiro, Roman Yelensky
  • Patent number: 11111537
    Abstract: This invention provides methods of using phagocytic cells alone or in combination with non-phagocytic cells in the diagnosis, prognosis, or monitoring of autoimmune or immune-related diseases or conditions. The invention also provides methods of using phagocytic cells alone or in combination with non-phagocytic cells to identify markers of autoimmune or immune-related diseases or conditions.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: September 7, 2021
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventor: Amin I. Kassis
  • Patent number: 11098302
    Abstract: Disclosed herein are compositions and methods for sequencing, analyzing, and utilizing samples such as single samples. Also disclosed herein are compositions and methods for matching together two or more sequences from a sample. Also disclosed herein are compositions and methods for expressing and screening molecules of interest.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: August 24, 2021
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States Government as Represented by the Department of Veterans Affair
    Inventors: William H. Robinson, Yann Chong Tan, Jeremy Sokolove
  • Patent number: 11098372
    Abstract: Disclosed is a gene expression panel that can be used to predict prostate cancer (PCa) progression. Some embodiments provide methods for predicting clinical recurrence of PCa. Some embodiments provide a method for treating a patient with prostate cancer, the method comprising: detecting expression levels of a collection of signature genes from a biological sample taken from said patient, wherein said collection of signature genes comprises at least NKX2-1; and correlating expression levels of said collection of signature genes with prostate cancer-related mortality to identify whether the patient is at risk of prostate cancer-related mortality.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: August 24, 2021
    Assignees: Illumina, Inc., University of Southern California
    Inventors: Mariana Carla Stern, Jacek Pinski, Jian-Bing Fan
  • Patent number: 11092603
    Abstract: The instant application relates to methods for determining pancreatic cancer patient outcome and directing treatment to subjects with pancreatic cancer. The present disclosure further provides methods for measuring expression levels of cytokeratin 17 in a subject having pancreatic cancer, such as pancreatic ductal adenocarcinoma, in order to determine the subject's survival rate and clinical outcome.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: August 17, 2021
    Assignee: The Research Foundation for The State University of New York
    Inventors: Kenneth R. Shroyer, Luisa F. Escobar-Hoyos
  • Patent number: 11086115
    Abstract: A microscope apparatus includes an illumination optical system that emits activating light and exciting light, an image capturing unit that captures an image formed by an imaging optical system, an image processing unit that carries out image processing using an image capturing result from the image capturing unit, and a controller. The controller provides a plurality of image generation periods and interrupt periods; causes, in the image generation periods, the activated fluorescent material to be irradiated with the exciting light and causes the image capturing unit to capture an image of the fluorescent light from the activated fluorescent material in a plurality of frame periods; and sets an intensity of the exciting light in the interrupt periods to be lower than an intensity in the image generation periods or causes the emission of the exciting light to stop in the interrupt periods.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: August 10, 2021
    Assignee: NIKON CORPORATION
    Inventors: Wataru Tomosugi, Kenji Takatsuka
  • Patent number: 11085046
    Abstract: Provided herein are compositions and methods for producing myrcene by culturing genetically modified microbial host cells that express a myrcene synthase and optionally a geranyl pyrophosphate synthase. Also provided herein are isolated nucleic acid molecules that encode myrcene synthase variants derived from the Ocimum species myrcene synthase, which comprise one or more amino acid substitutions that improve in vivo performance of myrcene synthase in genetically modified microbial host cells. Also provided herein are isolated myrcene synthase variants that exhibit an improved activity for converting geranyl diphosphate into myrcene.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: August 10, 2021
    Assignee: AMYRIS, INC.
    Inventors: Andrew Main, Grzegorz Wojciechowski, Yue Yang, Lishan Zhao
  • Patent number: 11079382
    Abstract: This disclosure describes methods, kits, and systems for scoring the immune response to cancer through examination of tissue infiltrating lymphocytes (TILs). Methods of scoring the immune response in cancer using tissue infiltrating lymphocytes include detecting CD3, CD8, CD20, and FoxP3 within the sample and scoring the detection manually or scoring the digital images of the staining with the aid of image analysis and algorithms.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: August 3, 2021
    Assignee: Ventana Medical Systems, Inc
    Inventors: Noemi Sebastiao, William Day, Robert Ochs, Srinivas Chukka, Jim Martin, Michael Barnes, Joerg Bredno, Ting Chen, Alisa Tubbs, Yao Nie
  • Patent number: 11079329
    Abstract: The present subject matter provides processes and kits for identifying the presence of waste water or human-derived pathogens, particularly those associated with the presence of human fecal matter, in surface or subsurface water sources.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: August 3, 2021
    Assignee: University of North Carolina Wilmington
    Inventors: Mary M. Turbe, Lawrence B. Cahoon
  • Patent number: 11078522
    Abstract: This disclosure provides microwell capsule array devices. The microwell capsule array devices are generally capable of performing one or more sample preparation operations. Such sample preparation operations may be used as a prelude to one more or more analysis operations. For example, a device of this disclosure can achieve physical partitioning and discrete mixing of samples with unique molecular identifiers within a single unit in preparation for various analysis operations. The device may be useful in a variety of applications and most notably nucleic-acid-based sequencing, detection and quantification of gene expression and single-cell analysis.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: August 3, 2021
    Assignee: 10X GENOMICS, INC.
    Inventors: Benjamin Hindson, Serge Saxonov, Michael Schnall-Levin
  • Patent number: 11060964
    Abstract: Provided is a cell detection method which makes it possible to effectively and accurately perform gene analysis only on target cells. The cell detection method includes a sorting step of obtaining first information derived from cells in a sample solution by using a flow cytometry method and sorting target cells into a container having arrays of wells each having an opening based on the first information, an imaging step of imaging the cells sorted into the container, and a determination step of obtaining second information derived from cells based on the image of the cells captured by the imaging step and determining cells to be analyzed from the sorted cells.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: July 13, 2021
    Assignee: FUJIFILM Corporation
    Inventor: Yasuhisa Kaneko
  • Patent number: 11060147
    Abstract: The present invention relates to methods for predicting acute severe colitis treatment response. Currently, there is no biomarker of drug response. The present invention provides the first prediction tool for responses to first- and second-line treatments in acute severe ulcerative colitis. Putative mRNA targets of dysregulated microRNAs were identified from patient biopsies. One classifier of fifteen colonic microRNAs plus five biological values at admission were identified with a prediction accuracy of 96.6% for discriminating responders from non-responders to steroids. Using a similar method, 6 and 4 mucosal microRNA-based algorithms were identified to classify responders from non-responders to infliximab and cyclosporine.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: July 13, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE PARIS, ASSISTANCE PUBLIQUE-HOPPITAUX DE PARIS (APHP), UNIVERSITE DE BORDEAUX, CHU DE BORDEAUX, UNIVERSITE PARIS XIII PARIS-NORD
    Inventors: Eric Ogier-Denis, Xavier Treton, Yoram Bouhnik, Ian Morilla, David Laharie, Gilles Wainrib, Mathieu Uzzan
  • Patent number: 11060102
    Abstract: Compositions and methods for improving plant growth are provided herein. Polynucleotides encoding photosystem I reaction center subunit N (PSAN) proteins, polypeptides encompassing PSAN proteins, and expression constructs for expressing genes of interest whose expression may improve agronomic properties including but not limited to crop yield, biotic and abiotic stress tolerance, and early vigor, plants comprising the polynucleotides, polypeptides, and expression constructs, and methods of producing transgenic plants are also provided.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: July 13, 2021
    Assignee: BENSON HILL, INC.
    Inventors: Benjamin Neil Gray, Henry D. Priest
  • Patent number: 11053551
    Abstract: A method of determining a probability that a human test subject has colorectal cancer as opposed to not having colorectal cancer is disclosed.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: July 6, 2021
    Assignee: StageZero Life Sciences Ltd.
    Inventors: Choong-Chin Liew, Samuel Chao
  • Patent number: 11053536
    Abstract: The present invention relates to a method, a device, and an apparatus for analyzing the expression of a gene in single cells. Specifically, the present invention relates to: a device for gene expression analysis, characterized by including a support, in which a nucleic acid probe having a test nucleic acid capture sequence and a known sequence, and further containing a cell recognition tag sequence which differs depending on the difference in position on the surface of the support or in the vicinity of the surface thereof, and a common primer sequence having a known sequence is two-dimensionally distributed and immobilized on the surface of the support or in the vicinity of the surface thereof; and a method and an apparatus using the device for gene expression analysis.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: July 6, 2021
    Assignee: Hitachi, Ltd.
    Inventors: Masataka Shirai, Hideki Kambara, Kiyomi Taniguchi, Maiko Tanabe
  • Patent number: 11053549
    Abstract: Disclosed is an in vitro method to diagnose or determine the risk of developing a neurodegenerative disease in a subject based on the determination of the methylation pattern in certain regions of mitochondrial DNA from the subject or the determination of the nucleotide at the polymorphic position 16519 in the mitochondrial DNA of the subject. Also, disclosed are nucleic acids suitable for the in vitro method to diagnose or determine the risk of developing a neurodegenerative disease in a subject.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: July 6, 2021
    Assignees: FUNDACIÓ INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL) S.A., UNIVERSITAT DE BARCELONA
    Inventors: Marta Barrachina Castillo, Isidre Ferrer Abizanda, Marta Blanch Lozano
  • Patent number: 11048729
    Abstract: A data manager determines an appropriate number of clusters for continuous data using unsupervised learning. The data manager selects an appropriate number of clusters based on at least one temporal stability measure between continuous data from at least two time intervals.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: June 29, 2021
    Assignee: International Business Machines Corporation
    Inventors: Omri Soceanu, Lev Greenberg, Allon Adir
  • Patent number: 11041193
    Abstract: Methods and devices are provided for simultaneously amplifying a plurality of sample wells for a predetermined amount of amplification, detecting whether amplification has occurred in a first set of the wells, amplifying for an additional amount of amplification and detecting whether amplification has occurred in a second set of the wells. Methods are also provided for analyzing a target nucleic acid sequence using melt curves that were generated in a plurality of amplification cycles.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: June 22, 2021
    Assignee: BioFire Diagnostics, LLC
    Inventors: Randy P. Rasmussen, Robert John Crisp, Andrew Clinton Hemmert, Elizabeth Barker Campbell, Thomas Charles Robbins, David J. Eyre
  • Patent number: 11043147
    Abstract: A method for asymmetric encryption based on a gene chip includes the steps of (a) obtaining original information in text or image or other form and converting the same into a binary code, and (b) preprocessing the binary code to obtain a binary matrix. In (c), an encryption key is obtained, the encryption key comprising a gene expression solution. In (d), the gene expression solution is placed on a gene chip according to an arrangement and correspondence of the binary matrix.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: June 22, 2021
    Assignee: AMBIT MICROSYSTEMS (SHANGHAI) LTD.
    Inventor: Jing Gao
  • Patent number: 11041164
    Abstract: The present disclosure provides methods for increasing drought resistance and heat resistance of a plant. The methods encompass expression of at least one heat shock protein (HSP) from the group consisting of HSP40, HSP60 or HSP70 together with a phosphoenolpyruvate carboxylase (PEPC) comprising an aspartic acid (D) at a position that corresponds to the position 509 of SEQ ID NO: 4, in the plant. In comparison to a plant not manipulated in this manner, the disclosed, genetically-modified, plants display improved drought resistance and heat resistance. Also provided are plants that can be obtained by the method according to the invention, and nucleic acid vectors to be used in the described methods.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: June 22, 2021
    Assignee: UT-BATTELLE, LLC
    Inventors: Xiaohan Yang, Gerald A. Tuskan, Degao Liu, Rongbin Hu, Jin-Gui Chen, Meng Xie
  • Patent number: 11035000
    Abstract: Disclosed are compositions and methods for enriching a non-host sequence from a host sample. Also disclosed are compositions and methods for detecting a non-host sequence in a host sample. For example, a pathogen can be enriched and detected in a sample taken from a human without knowing what the pathogen is.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: June 15, 2021
    Assignee: UNIVERSITY OF ALASKA FAIRBANKS
    Inventors: Jiguo Chen, Fang Ge
  • Patent number: 11037292
    Abstract: An evaluator 21 that evaluates states of cells included in each region of interest of a cell image, and a predictor 22 that performs, in advance, machine learning of a relationship between evaluation results for a specific region of interest within a first cell image obtained by imaging cells before a staining process and regions around the specific region of interest and staining states of cells of the specific region of interest within a second cell image obtained by imaging the same imaging targets as the cells of the first cell image after the staining process are provided. The predictor 22 predicts staining states of cells of a specific region of interest based on evaluation results for the specific region of interest and regions around the specific region of interest among the evaluation results for the third cell image of the cells before the staining process.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: June 15, 2021
    Assignee: FUJIFILM Corporation
    Inventor: Takashi Wakui
  • Patent number: 11029320
    Abstract: Identification and use of proteins fluorescently labeled and that undergo a change in fluorescence index upon binding bilirubin are described. Probes are disclosed which are labeled at a cysteine or lysine residue and also probes labeled at both cysteine and lysine with two different fluorophores. These probes are useful for determination of unbound bilirubin levels in a fluid sample.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: June 8, 2021
    Inventor: Alan Marc Kleinfeld
  • Patent number: 11031119
    Abstract: Deep learning of dental images for national security is described. A computer may receive dental images of a patient from a dental provider. The computer is configured to match dental images to law enforcement databases such as a terrorist database. The process begins with matching a dental image to an anatomy probability dataset and a pathology probability dataset, then correlating it with a patient database to identify a person of interest. With different resolutions each neural network deep learns to probability map and detect different dental object probabilities to authenticate an individual. Further, the dental images will be associated with GPS coordinates to track movements of an individual. The datasets will be provided to e-commerce providers, e-commerce consumers, e-commerce administrators, machine learning entities, government entities and law enforcement entities which may exchange or transfer the data over a communication network such as the internet to locate a person of interest.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: June 8, 2021
    Assignee: Cube Click, Inc.
    Inventors: Richard Ricci, Andrea Cambria
  • Patent number: 11021755
    Abstract: In alternative embodiments, provided are products of manufacture, such as assays, chimeric nucleic acids and nucleic acid constructs, recombinant cells, and methods, comprising use of beta3-integrin (ITGB3) promoters operatively linked to a reporter, for drug screening, and in particular, screening for agents that inhibit cancer cell survival and metastasis. In alternative embodiments, compositions and methods as provided herein also can be used to identifying novel pathways that lead to acquired resistance, stemness, and anchorage independent growth; and characterizing distinct populations of cancer cells within a tumor microenvironment.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: June 1, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: David Cheresh, Maricel Gozo, Mayra Yebra, Laetitia Seguin
  • Patent number: 11021733
    Abstract: The present invention provides methods, compositions and devices for stabilizing the extracellular nucleic acid population in a cell-containing biological sample using an apoptosis inhibitor, preferably a caspase inhibitor, a hypertonic agent and/or a compound according to formula 1 as defined in the claims.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: June 1, 2021
    Assignee: Qiagen GmbH
    Inventors: Martin Horlitz, Annabelle Schubert, Markus Sprenger-Haussels
  • Patent number: 11022601
    Abstract: Pre-existing alloreactive memory T cells are a major barrier to the induction of allograft tolerance in organ transplant recipients. The use of Eomesodermin (Eomes) expression in memory T cells to determine the risk of allograft rejection in a subject is described. Also described is the use of Eomes expression in memory T cells of transplant recipients to modify immunosuppressive therapy.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: June 1, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Mohamed B. Ezzelarab, Angus W. Thomson
  • Patent number: 11021737
    Abstract: Methods of making a three-dimensional matrix of nucleic acids within a cell is provided.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: June 1, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: George M. Church, Je-hyuk Lee, Daniel Levner, Michael Super
  • Patent number: 11017881
    Abstract: A representation of a nucleic acid sequence encodes a particular gene having at least one intron. An intron signature value corresponding to the at least one intron is determined based on a first computational function applied to at least one portion of the representation of the nucleic acid sequence corresponding to the at least one intron. A protein signature value is determined, being based on a second computational function applied to a representation of a protein. In a database, an association is formed between the intron and protein signature values. This process is repeated for each of a plurality of nucleic acid sequences. Nucleic acid sequences in the database are ordered based on a sort of corresponding intron signature values. An ordering determined by the sort is used to determine or confirm a role or function of a portion of a given nucleic acid sequence.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: May 25, 2021
    Assignee: CODONDEX LLC
    Inventors: Kevin Bermeister, Xinghao Yu
  • Patent number: 11015190
    Abstract: A method of making a prognosis as to whether a patient having renal cancer is likely to survive in a tumour tissue sample obtained from the patient is provided. The method comprising determining the level of expression for each marker of a panel of markers comprising at least one housekeeping gene selected from the group consisting of ACTB, RPL13A, RPL9, and RPS29 and any combinations thereof and at least one prognostic gene selected from the group consisting of CXCL5, EFNA5, EMCN, G6PC, GFPT2, HIST2H3C, IGFBP1, LAMB3, MMP9, MOCOS, PLG, PRAME, RARRES1, SDPR, SLC6A19, TK1, KDELR3 and TSPAN7 and any combinations thereof, comparing the level of expression of each marker with a predetermined reference level associated with each marker, and determining the differential expression of each marker in the tumour tissue sample based on the expression parameter for each marker to provide a prognosis for renal cancer.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: May 25, 2021
    Assignee: Lucence Life Sciences Pte Ltd
    Inventors: Min-Han Tan, Yukti Choudhury, Puay Hoon Tan, Bin Tean Teh
  • Patent number: 11015221
    Abstract: The present invention concerns methods for determining if a dendritic cell is a type 2 dendritic cell or a tolerogenic dendritic cell, methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector type 2 cell response, and methods of determining response to immunotherapy.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: May 25, 2021
    Assignee: STALLERGENES
    Inventors: Laurent Mascarell, Claire Gueguen, Emmanuel Nony, Philippe Moingeon, Véronique Bodo
  • Patent number: 11008625
    Abstract: A method for detecting a target nucleic acid sequence in a sample in the presence of at least protein capable of binding to single-stranded DNA is provided, comprising contacting said sample with at least one oligonucleotide probe comprising a fluorophore, a quencher and a region complementary to said target nucleic acid sequence. The sequence of the oligonucleotide probe comprises at least 20% RNA nucleotides, modified RNA nucleotides and/or PNA nucleotides.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: May 18, 2021
    Assignee: AIDIAN OY
    Inventors: Kevin Eboigbodin, Mirko Brummer
  • Patent number: 11002737
    Abstract: The present disclosure provides micro-array devices for capturing cells in blood and methods of their use. In some aspects, a method for counting cells in a blood sample is provided, the method comprising applying a blood sample onto a CNT device; allowing cells in the blood sample to differentially settle on the CNT device, and identifying and counting cells of preselected type in the blood sample.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: May 11, 2021
    Assignees: Worcester Polytechnic Institute, University of Louisville Research Foundation, Inc.
    Inventors: Balaji Panchapakesan, Farhad Khosravi, Shesh N. Rai
  • Patent number: 10986827
    Abstract: One variation of a method for interpreting pressures in plants includes: accessing a first image of a first set of sentinel plants in a field; accessing a second image of a second set of sentinel plants in the field, recorded during a first period; interpreting a first pressure of a stressor in the first set based on features extracted from the first image, captured during the first period; interpreting a second pressure in the second set based on features extracted from the second image; deriving a model associating pressure at the first set and pressure at the second set based on the first pressure and the second pressure; interpreting a third pressure in the first set based on features extracted from a third image captured during a second period; and predicting a fourth pressure in the second set during the second period based on the third pressure and the model.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: April 27, 2021
    Assignee: InnerPlant, Inc.
    Inventors: Shely Aronov, Roderick Kumimoto, Ari Kornfeld
  • Patent number: 10988816
    Abstract: Disclosed are nucleic acid oligomers, including amplification oligomers, capture probes, and detection probes, for detection of a human papillomavirus (HPV) nucleic acid. Also disclosed are methods of specific nucleic acid amplification and detection using the disclosed oligomers, as well as corresponding reaction mixtures and kits.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: April 27, 2021
    Assignee: GEN-PROBE INCORPORATED
    Inventor: Astrid R. W. Schroder
  • Patent number: 10982281
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual to treatment of cardiovascular disorders with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: April 20, 2021
    Assignee: Celera Corporation
    Inventors: Olga Iakoubova, James J. Devlin, Zenta Tsuchihashi, Peter Shaw, Lynn Marie Ploughman, Kim E. Zerba, Koustubh Ranade, Todd Kirchgessner
  • Patent number: 10975378
    Abstract: Compositions and methods are disclosed herein for cloning a synthetic or a semi-synthetic donor genome in a heterologous host cell. In one embodiment, the donor genome can be further modified within a host cell. Modified or unmodified genomes can be further isolated from the host cell and transferred to a recipient cell. Methods disclosed herein can be used to alter donor genomes from intractable donor cells in more tractable host cells.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: April 13, 2021
    Assignee: Codex DNA, Inc.
    Inventors: Vladimir N. Noskov, Ray-Yuan Chuang
  • Patent number: 10964410
    Abstract: The present disclosure pertains to a system, a method of using such a system, and a non-transitory computer-readable medium containing instructions to such a system for generating annotated gene fusion data from processing both a patient's DNA and RNA sequence information thereby filtering out weak candidate gene fusions. Thus the annotated gene fusion data contains clinically relevant information and accurate gene fusion detections (low false-positives) for use in clinical and/or R&D settings. The system, method and computer-readable medium allows a user to generate gene fusion data by detecting breakpoints from a patient's DNA-SEQ and RNA-SEQ, creating candidate breakpoint data by combining matching breakpoints from the DNA-SEQ and RNA-SEQ breakpoint data, determining confidence levels of the candidate breakpoint, identifying corresponding gene fusions, and annotating clinically relevant information about the gene fusions.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: March 30, 2021
    Assignee: Koninklijke Philips N.V.
    Inventors: Yong Mao, Nevenka Dimitrova, Kostyantyn Volyanskyy
  • Patent number: 10962554
    Abstract: The present invention concerns subject matter connected to or making use of IgLON5, IgLON5 fragments and variants of IgLON5 and IgLON5-fragments. In particular the present invention relates to a use of a polypeptide comprising one or more sequences of IgLON5, an IgLON5-fragment or a variant thereof for the diagnosis of a disease, in vitro methods for diagnosing such a disease, a polypeptide comprising one or more sequences of IgLON5, an IgLON5-fragment or a variant thereof or a nucleic acid encoding said polypeptide for use in the treatment of a disease, a pharmaceutical composition comprising such polypeptide, a method for treating such a disease, an autoantibody binding to IgLON5, an IgLON5-fragment or a variant thereof, a method for isolating such autoantibody, a medical or diagnostic device comprising such autoantibody or such polypeptide and a test kit for the diagnosis of a disease, which test kit comprises such autoantibody and/or such polypeptide.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: March 30, 2021
    Assignees: INSTITUT D'INVESTIGACIONES BIOMÈDIQUES AUGUST PI I SUNYER, INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS, UNIVERSITÄT DE BARCELONA, HOSPITAL CLÍNIC DE BARCELONA
    Inventors: Josep Dalmau, Francesc Graus
  • Patent number: 10964519
    Abstract: The invention relates to an apparatus for mass-spectrometric analysis and three-dimensional imaging of the surface of a sample, comprising at least one energy source for desorbing and/or ionizing atoms from the surface of a sample, a displacement stage, and a light source. Further, it comprises an interface in order to be able to interchange data with a mass spectrometer such that measurement data can be transmitted from a mass spectrometer to the evaluation unit via the interface such that the chemical composition of the measurement point can be determined by the evaluation unit. The surface of a sample can be captured in three dimensions and the topography of this surface can be determined by the evaluation unit.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: March 30, 2021
    Assignee: JUSTUS-LIEBIG-UNIVERSITAET GIESSEN
    Inventors: Bernhard Spengler, Mario Kompauer
  • Patent number: 10955362
    Abstract: This disclosure relates to methods for determining the quality of polymers, more particularly, polyolefins. The methods involve Raman spectroscopy and artificial intelligence to compute polymer properties and/or features.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: March 23, 2021
    Assignee: BRASKEM AMERICA, INC.
    Inventor: Gustavo A. Guzman Cardozo
  • Patent number: 10954290
    Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: March 23, 2021
    Assignee: BIOTEST AG
    Inventors: Wolfgang Möller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun